Patents by Inventor David Scadden
David Scadden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220016106Abstract: The present invention includes methods of treating patients with acute myeloid leukemia across a range of genetic subtypes with DHODH inhibitors, such as 6-fluoro-2-(2?-fluoro-[1,1?-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid).Type: ApplicationFiled: July 22, 2021Publication date: January 20, 2022Applicants: THE BROAD INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, BAYER PHARMA AKTIENGESELLSCHAFTInventors: David B. Sykes, David Scadden, Timothy A. Lewis, Andreas Janzer, Hanna Meyer, Detlef Stöckigt
-
Patent number: 11096934Abstract: The present invention includes methods of treating patients with acute myeloid leukemia across a range of genetic subtypes with DHODH inhibitors, such as 6-fluoro-2-(2?-fluoro-[1,1?-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid).Type: GrantFiled: August 29, 2016Date of Patent: August 24, 2021Assignees: THE BROAD INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, BAYER PHARMA AKTIENGESELLSCHAFTInventors: David B. Sykes, David Scadden, Timothy A. Lewis, Andreas Janzer, Hanna Meyer, Detlef Stöckigt
-
Publication number: 20190000885Abstract: Aspects of the technology disclosed herein generally (and in part) relates to use of Angiogenin (ANG) for increasing hematopoietic reconstitution of in vivo hematopoietic cells and transplanted hematopoietic cells. Provided herein are methods and compositions useful in treatment of diseases characterized by decreased levels of hematopoietic cells, decreased levels of hematopoietic reconstitution, blood cell deficiency and prevention and treatment of radiation injury. One aspect relates to angiogenin treated hematopoietic cell compositions and methods of their use in stem cell transplantation. Treatment of hematopoietic cells with angiogenin enhances quiescence and reduces proliferative capacity of primitive hematopoietic stem cells while increasing proliferation of myeloid restricted progenitor cells. Another aspect relates to use of ANG in prophylactic and therapeutic treatment methods for radiation injury.Type: ApplicationFiled: November 29, 2016Publication date: January 3, 2019Applicants: THE GENERAL HOSPITAL CORPORATION, TUFTS MEDICAL CENTER, INC., TRUSTEES OF TUFTS COLLEGE, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: David SCADDEN, Peter KHARCHENKO, Lev SILBERSTEIN, Guo-fu HU, Kevin GONCALVES
-
Publication number: 20180263970Abstract: The present invention includes methods of treating patients with acute myeloid leukemia across a range of genetic subtypes with DHODH inhibitors, such as 6-fluoro-2-(2?-fluoro-[1,1?-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid).Type: ApplicationFiled: August 29, 2016Publication date: September 20, 2018Applicants: THE BROAD INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, BAYER PHARMA AKTIENGESELLSCHAFTInventors: David B. Sykes, David Scadden, Timothy A. Lewis, Andreas Janzer, Hanna Meyer, Detlef Stöckigt
-
Publication number: 20170131280Abstract: The technology described herein is directed to methods, assays, and systems relating to determining the level of SAKT signaling activity in a sample obtained from a subject as well as methods relating to administering inhibitors and/or agonists of SAKT signaling.Type: ApplicationFiled: September 23, 2016Publication date: May 11, 2017Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: David SCADDEN, Dongjun LEE
-
Publication number: 20140363449Abstract: The technology described herein is directed to methods, assays, and systems relating to determining the level of SAKT signaling activity in a sample obtained from a subject as well as methods relating to administering inhibitors and/or agonists of SAKT signaling.Type: ApplicationFiled: February 20, 2013Publication date: December 11, 2014Inventors: David Scadden, Dongjun Lee
-
Patent number: 8828965Abstract: The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.Type: GrantFiled: August 21, 2013Date of Patent: September 9, 2014Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Massachusetts Institute of TechnologyInventors: Jun Lu, Shangqin Guo, Benjamin Ebert, David Scadden, Todd Golub
-
Publication number: 20140050707Abstract: The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.Type: ApplicationFiled: August 21, 2013Publication date: February 20, 2014Applicants: THE GENERAL HOSPITAL CORPORATION, DANA-FARBER CANCER INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Jun Lu, Shangqin Guo, Benjamin Ebert, David Scadden, Todd Golub
-
Patent number: 8642569Abstract: Described herein are methods and compositions for expanding hematopoietic stem and progenitor cells (HSPC) ex vivo and in vivo, and methods and compositions for transplanting HSPCs and treatment of anemia in a human subject. HSPCs are expanded in the presence of an inhibitor of serine threonine kinase 38 (STK38), wherein said inhibitor is preferably an RNAi agent.Type: GrantFiled: January 21, 2010Date of Patent: February 4, 2014Assignee: The General Hospital CorporationInventors: David Scadden, Jonas Larsson
-
Patent number: 8530443Abstract: The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.Type: GrantFiled: October 16, 2012Date of Patent: September 10, 2013Assignees: The General Hospital Corporation, Massachusetts Institute of Technology, Dana-Farber Cancer Institute, Inc.Inventors: Jun Lu, Shangqin Guo, Benjamin Ebert, David Scadden, Todd Golub
-
Publication number: 20130039895Abstract: The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.Type: ApplicationFiled: October 16, 2012Publication date: February 14, 2013Applicants: THE GENERAL HOSPITAL CORPORATION, DANA-FARBER CANCER INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Jun Lu, Shangqin Guo, Benjamin Ebert, David Scadden, Todd Golub
-
Publication number: 20110280861Abstract: Embodiments of the invention relate to methods and compositions for the expansion of hematopoietic stem cell (HSC) self renewal. The microRNA-125a is a master control of HSC self-renewal. Increased expression of mir-125a increased HSC self-renewal by 6-30 folds. Increased expression of mir-125a can be used to expand HSC ex vivo and in vivo.Type: ApplicationFiled: August 10, 2009Publication date: November 17, 2011Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE GENERAL HOSPITAL CORPORATIONInventors: David Scadden, Shangqin Guo, Jun Lu
-
Publication number: 20090202493Abstract: The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.Type: ApplicationFiled: January 30, 2009Publication date: August 13, 2009Applicants: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Jun Lu, Shangqin Guo, Benjamin Ebert, David Scadden, Todd Golub
-
Publication number: 20080064101Abstract: The invention relates to a method for lymphoid tissue-specific cell production from hematopoietic progenitor cells in unique, three-dimensional culture devices, in the presence of antigen presenting cells and lymphoreticular stromal cells, and in the absence of exogenously added growth factors. The resulting lymphoid tissue-specific cells may be isolated at any sequential stage of differentiation and further expanded. The lymphoid tissue-specific cells also may be genetically altered at any stage of the process.Type: ApplicationFiled: January 31, 2007Publication date: March 13, 2008Applicants: Cytomatrix, LLC, The General Hospital CorporationInventors: Mark Pykett, Michael Rosenzweig, David Scadden, Mark Poznansky
-
Publication number: 20080057579Abstract: The invention relates to methods for manipulating hematopoietic stem cells and related products. In one aspect the invention relates to the use of stem cell G-protein coupled receptor (SC-GPR) related compositions to identify bone marrow derived hematopoietic stem cells, to enhance mobilization of hematopoietic stem cells, to improve the efficiency of targeting cells to the bone marrow and/or to modulate hematopoietic cell function.Type: ApplicationFiled: July 2, 2007Publication date: March 6, 2008Applicant: The General Hospital CorporationInventors: David Scadden, Byeong-Chel Lee
-
Publication number: 20070281889Abstract: The invention relates to methods for manipulating hematopoietic stem or progenitor cells, mesenchymal stem cells, epithelial stem cells, neural stem cells and related products through activation of the PTH/PTHrP receptor in neighboring cells.Type: ApplicationFiled: November 8, 2005Publication date: December 6, 2007Inventors: David Scadden, Laura Calvi, Gregor Adams, Henry Kronenberg
-
Publication number: 20070026007Abstract: This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of cells of hematopoietic, neural, epithelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific. sites in a subject. More specifically, specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. Other sites include tumor sites, sites of pathogenic infection, and germ cell bearing sites.Type: ApplicationFiled: April 20, 2006Publication date: February 1, 2007Inventors: Mark Poznansky, Andrew Luster, David Scadden
-
Publication number: 20060292689Abstract: This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of CaR receptor expressing cells of hematopoietic, neural, epithelial, endothelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject. Specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. The invention also relates to methods for manipulating hematopoeitic progenitor cells and related products.Type: ApplicationFiled: May 8, 2006Publication date: December 28, 2006Inventors: Mark Poznansky, Edward Brown, David Scadden, Ivona Olszak
-
Publication number: 20060257376Abstract: The invention relates to methods for manipulating hematopoietic progenitor cells and related products. In one aspect the invention relates to the use of agents that activate a PTH/PTHrP receptor to enhance the growth and maintenance of hematopoietic progenitor cells in vivo and in vitro, to enhance mobilization of hematopoietic stem cells, to improve the efficiency of targeting cells to the bone marrow, and/or to modulate hematopoietic progenitor cell function.Type: ApplicationFiled: July 25, 2003Publication date: November 16, 2006Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: David Scadden, Laura Calvi, Gregor Adams, Henry Kronenberg